AdAlta validates platform through US$120M agreement
- Ori Biotech executed a 10-year partnership valued at US$120 million to advance automated cell therapy manufacturing for commercial therapies.
- The agreement validates AdAlta's selection of the IRO automated platform for its cellular immunotherapy pipeline.
- The collaboration aims to address cell therapy challenges by cutting production costs and increasing manufacturing throughput.
AdAlta (ASX:1AD) confirmed that manufacturing partner Ori Biotech signed a 10-year agreement valued at US$120 million to advance commercial-scale cell therapy production.
The transaction provides commercial validation for the IRO platform that AdAlta selected to manufacture its cellular immunotherapy pipeline.
"Our strategy depends on showing partners that our therapies are not only effective but can be manufactured at scale, cost-effectively, and transferred easily between sites," said AdAlta CEO Dr Tim Oldham.
The IRO platform automates labour-intensive production steps, targeting potential cost savings between 30% and 50% alongside higher manufacturing throughput.
The partnership supports AdAlta's pipeline deployment across global markets as the company expands its cellular immunotherapy capabilities.
Following the announcement the AdAlta share price was unchanged at $0.0030.
The biotechnology company focuses on developing protein and cell therapies for solid cancers through its proprietary technology platforms.
AdAlta operates a multi-partner model in Australia and the Asia-Pacific region to deliver scalable cell therapy manufacturing solutions.
